Global Musculoskeletal Market Insights Forecasts to 2033

• The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033
• The Worldwide Musculoskeletal Market Size is Expected to Hold a Significant Share by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Musculoskeletal Market Size is Expected to Hold a significant share by 2033, Growing at a Substantial CAGR of 6.2% from 2023 to 2033.

Market Overview

Musculoskeletal disorders are injuries or illnesses that affect the musculoskeletal system of the human body. The muscles, ligaments, nerves, tendons, spinal discs, and cartilage are among the parts damaged or affected. Osteoarthritis, gout, osteoporosis, rheumatoid arthritis, and back pain are the most prevalent musculoskeletal conditions. The wear and tear of regular activities damages muscle tissue, leading to musculoskeletal pain. According to the WHO reports, Worldwide, 1.71 billion people suffer from musculoskeletal disorders. NSAIDs, physical activity, acupuncture, heat and cold therapy, and steroids are among the main therapies for MSD. The market for musculoskeletal disorders is boosted by the ageing population, rising public knowledge of the condition's prevention and treatment, and improved treatment alternatives. Encouraging worldwide government initiatives, expanding healthcare spending, and introducing musculoskeletal illness treatments are boosting market growth. Furthermore, emerging nations have a very high prevalence of unmet medical requirements, which is likely to foster market expansion. Consequently, market participants in developing nations have abundant opportunities to drive the musculoskeletal disorders market by implementing musculoskeletal disease medications. Treatment-related technological developments contribute to market expansion.

Report Coverage

This research report categorizes the market for the musculoskeletal market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the musculoskeletal market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the musculoskeletal market.

Driving Factors

The ongoing advancement of technologies used to diagnose and treat musculoskeletal disorders. Recently developed diagnostic tools for musculoskeletal issues are more adaptable and practical. The most recent methods, such as stem cell research, small molecules, biologics, and others, contribute to the improvement of medication and therapy accuracy. Treatment options for musculoskeletal problems are improved by techniques including gene therapy, orthobiologics, organ-on-a-chip, lab-on-a-chip, and orthobiologics. Furthermore, procedures like bone grafting aid in the repair of broken bones. Better care services as well as extensive research and development are therefore anticipated to boost market growth.

Restraining Factors

The high cost of diagnosing and treating musculoskeletal disorders may limit the market's growth potential. The reason why the patient cannot afford sophisticated diagnostic procedures like CT and MRI scans is due to their astronomical costs. In addition, the exorbitant expenses associated with treatment encourage improper MSD care, which deters root-cause treatment.

Market Segmentation

The musculoskeletal market share is classified into type and type of molecules.

• The osteoarthritis segment is expected to hold the largest share of the musculoskeletal market during the forecast period.   

Based on the type, the musculoskeletal market is categorized into rheumatoid arthritis, osteoarthritis, osteoporosis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others. Among these, the osteoarthritis segment is expected to hold the largest share of the musculoskeletal market during the forecast period. Osteoarthritis is a widespread chronic joint disorder that affects millions of people throughout the world. It is a major contributor to disability and primarily affects the elderly, whose numbers are rising as a result of global aging trends. The increased market demand for osteoarthritis therapies is directly correlated with this high prevalence.

• The biologics segment is expected to grow at the fastest CAGR during the forecast period.   

Based on the type of molecules, the musculoskeletal market is categorized into biologics and small molecules. Among these, the biologics segment is expected to grow at the fastest CAGR during the forecast period. The segment's focus on biologics because of their intricate structure, which makes them difficult to identify or characterize. For individuals with psoriatic, rheumatoid, and other inflammatory arthritis, biologics medications are effective and durable. Furthermore, biologics products are heavily utilized in biopharmaceuticals for drug development and research, which supports the expansion of the market growth.

Regional Segment Analysis of the Global Musculoskeletal Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the musculoskeletal market over the forecast period.

North America is projected to hold the largest share of the musculoskeletal market over the forecast period. The musculoskeletal market has the greatest room to grow in the North American area, where the US and Canada emerge as the leading contributors. Globally, the US and Canada are among the nations where MSD prevalence is highest. The region's market has room to grow because of the growing number of people with MSDs as a result of obesity and bad lifestyles, more awareness, and improved treatment options. According to Liberty Mutual, the nation's largest workers' compensation insurance company, overexertion injuries lifting, pushing, tugging, holding, carrying, or tossing an object cost business $13.4 billion per year. The market for musculoskeletal diseases is expanding because of the rising incidence of these conditions.

Asia Pacific is expected to grow at the fastest CAGR growth of the musculoskeletal market during the forecast period. Modern research and development, sophisticated healthcare facilities, and an ageing population are all contributing factors. In addition, the MSD treatment market in nations like China, India, and Japan is supported by conventional medications and therapies like acupuncture. The worldwide population is ageing, and medical technology advancements and raised awareness are the main factors driving the industry. But to guarantee increased access and better treatment results, issues like exorbitant pricing and regulatory obstacles need to be resolved.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the musculoskeletal market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Zimmer Biomet Holdings, Inc.
• Stryker Corporation
• Medtronic
• Sanofi S.A
• Bristol-Myers Squibb
• Eli Lilly And Company
• Mitsubishi Tanabe Pharma Corporation
• EverEx
• Horizon Therapeutics plc
• Procter & Gamble
• Eisai Co. Ltd
• Others

Key Market Developments

• In July 2024, The US-based medical device business Stryker has declared that it had successfully acquired Artelon, a soft tissue fixation company, in order to increase its market share in surgery, which is estimated to be worth USD 3.4 billion.

• In March 2024, EverEx, a Korean firm, offered a digital treatment for MORA, a musculoskeletal condition. AI is used by MORA to create, evaluate, and recommend rehabilitation exercises based on patient-related data.

• In October 2023, Amgen announced that it has successfully acquired Horizon Therapeutics plc for cash for $116.50 per share, for a total transaction equity value of about $27.8 billion.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global musculoskeletal market based on the below-mentioned segments: 

Global Musculoskeletal Market, By Type

• Rheumatoid Arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Fibromyalgia
• Others

Global Musculoskeletal Market, By Type of Molecule

• Biologics
• Small Molecules

Global Musculoskeletal Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa